How to appeal a Humana spinal muscular atrophy denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for spinal muscular atrophy

Cited policy: Humana Non-Invasive Ventilation (BiPAP) + Cough Assist for Neuromuscular Disease

Documented neuromuscular disease (SMA G12.0/G12.1/G12.9). FVC <60% predicted (age >=5 yr) OR symptomatic nocturnal hypoventilation OR sleep study showing OSA/hypoventilation OR cough peak flow <270 L/min. Pulmonologist or neuromuscular specialist Rx. Mechanical insufflation-exsufflation (cough-assist) as adjunct.

How Humana denies spinal muscular atrophy — and how to counter it

Where Humana pushes back: 1) FVC threshold not met; 2) Sleep study not performed; 3) Pediatric FVC not testable; 4) Cough-assist deemed not medically necessary.

Counter-arguments that hold up: SMA Standards of Care 2018 Part 2 (Finkel Mercuri Meyer Neuromuscul Disord 2018;28(3):197-207) endorse proactive NIV for symptomatic nocturnal hypoventilation regardless of FVC threshold; in pediatric patients <5 yr where FVC is not testable, clinical signs (paradoxical breathing, retractions, sleep-disordered breathing) and symptomatic indications drive initiation. Cough-assist is indicated alongside NIV per consensus (peak cough flow <270 L/min in older children). AANEM and Cure SMA endorse early respiratory intervention per ICTUS framework. Submit sleep study + capnography + clinical symptoms + neuromuscular specialist letter.

What Humana typically denies for spinal muscular atrophy

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For spinal muscular atrophy, expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the spinal muscular atrophy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Spinraza (nusinersen)
• Evrysdi (risdiplam)
• Zolgensma (onasemnogene)
• Combination/sequential
• Switching therapy
• BiPAP / NIV

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.